

FIGURE 1





FIGURE 2: AZOLE NUCLEOSIDE ISOMERS



Ribavirin	
Cells	CC_{50} , μM
MDBK	: 5
HepG2	: 90
PBM	: >100
Vero	: >100
CEM	: 75

FIGURE 3: CYTOPATHIC EFFECT (CPE) ASSAY




FIGURE 4: TOXICITY OF C2-MAD IN BALB/C MICE




FIGURE 5: STANDARD CURVE FOR BVDV




FIGURE 6: GROWTH DYNAMICS OF BVDV IN MDBK CELLS




FIGURE 7: BVDV IN MDBK SUPERNATANT OVER A 4-DAY INCUBATION PERIOD




FIGURE 8: ANTI-BVDV COMPOUND (40 μ M) IN MDBK CELLS

NO: No Treatment;

RIB: Ribavirin;

A: β -CH₂-TAD;

B: Benzamide Riboside;

C: C2-MAD;

D: C2-MPAcid;

E: C2-MPAAldehyde;

F: C4-MPAcid;

G: C4-MPAAldehyde;

H: C6-MAD;

I: F-ara-CH₂-BAD;

J: F-ara-TAD;

K: MPA;

L: Benzyl-C2-MPA-O-Mesyl;

M: Tiazofurin;

N: Mizoribine




FIGURE 9: DOSE RESPONSE OF C2-MAD RELATIVE TO RIBAVIRIN (RIB) AND TIAZOFURIN




FIGURE 10: ANTIVIRAL EFFECT AFTER ADDITION OF EXOGENOUS GUANOSINE